CAPR News

CAPR Shareholder Alert: Capricor Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky

Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff Deadline

Kaplan Fox Alerts Investors to a Deadline for a Securities Fraud Class Action Lawsuit Against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on September 28, 2026

Recover Investment Losses: Class Action Initiated Against Capricor Therapeutics, Inc. (CAPR)

Pomerantz LLP Issues Reminder to Shareholders in Capricor Therapeutics, Inc. of Class Action Filing – CAPR

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Rackspace Technology, Inc. (RXT), Capricor Therapeutics, Inc. (CAPR), and Wise Group plc (WSE) Announced by Holzer & Holzer, LLC

CAPR Investment Losses: Capricor Therapeutics Clinical Data Announcement Leads to 64% Stock Drop – BFA Law Reminds Investors of the Pending Securities Fraud Class Action

Did You Lose Money on Capricor Therapeutics, Inc. (CAPR)? Levi & Korsinsky Urges Investors to Act Before September 28, 2026

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law